glp-1 physiology informs the pharmacotherapy of obesity Glucagon-like peptide-1 receptor agonism and end-organ protection: Trends in Endocrinology & Metabolism Pharmacotherapy of Weight‐loss and Obesity

Esta doble accin mejora el control glucmico sin aumentar significativamente el riesgo de hipoglucemia cuando se usa como monoterapia

He practices traditional endocrinology at Endo of Fairfield and functional/regenerative medicine at Restore Health LLC in Fairfield, CT.

Prolactin at 8 weeks for GHRP-2 specifically

Personalization : Dosages may need to be adjusted based on your response to the peptides

Tirzepatide works on two hormone receptors (GIP + GLP-1) while semaglutide only targets GLP-1

Patients who advance doses gradually and maintain consistent hydration report dizziness rates closer to 2-3%, suggesting that dosing speed and fluid management are modifiable risk factors